Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.
This study is recruiting in multiple countries, including in the United States, in Argentina, and in Australia. It is testing KarXT for manic episodes in bipolarity type I.
This study is recruiting in multiple countries, including in the United States, in Argentina, and in Australia. It is testing KarXT for manic episodes in bipolarity type I.
This study is looking at whether Cool roof can help people with depression. Participants take part in Cool roof and complete follow-up assessments.
This study is looking at whether a digital support tool can help people with Depression, Mental and Behavioural Disorders, or Depressive episode, unspecified. Participants receive a study treatment and complete follow-up visits and assessments.
This observational study is following people with Depressive symptoms, including anxiety and other mental and/or chronic physical health comorbidities or Mental and Behavioural Disorders to understand outcomes over time. Participants mainly provide questionnaire, assessment, or follow-up information rather than receiving a new study treatment.
This study exists to understand how this type of care holds up over time after the earliest research stage. Researchers are trying to understand whether this type of care can better support energy, concentration, and everyday functioning.
This study has public registry information in multiple countries, including in Argentina, in Australia, and in Austria. It focuses on schizophrenia.
This study exists to learn from real-world information that can show how the medication Iclepertin fits into care. Researchers are trying to understand whether the medication Iclepertin can improve attention, thinking, or day-to-day functioning.
This study is completed in multiple countries, including in Australia, in China, and in Malaysia. It focuses on schizophrenia.
This study is completed in multiple countries, including in Australia, in Canada, and in France. It focuses on schizophrenia.